ENTA
NASDAQ · Biotechnology
Enanta Pharmaceuticals Inc
$13.93
+0.21 (+1.53%)
Open$13.82
Previous Close$13.72
Day High$14.21
Day Low$13.72
52W High$17.15
52W Low$6.44
Volume—
Avg Volume170.3K
Market Cap368.13M
P/E Ratio—
EPS$-2.59
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+219.8% upside
Current
$13.93
$13.93
Target
$44.55
$44.55
$33.16
$44.55 avg
$53.28
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 89.81M | 98.51M | 75.01M |
| Net Income | -112,583,950 | -111,139,141 | -19,564,680 |
| Profit Margin | -125.4% | -119.1% | -26.1% |
| EBITDA | -111,035,154 | -115,699,677 | -21,379,947 |
| Free Cash Flow | — | — | -13,998,479 |
| Rev Growth | -8.8% | -8.8% | -3.9% |
| Debt/Equity | 2.21 | 2.21 | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $243.73 | +3.76% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $356.32 | +1.39% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $124.43 | -0.58% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $484.49 | +1.96% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $625.11 | +0.27% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $291.90 | -0.73% | 64.3 | 37.13B |